Erectile Dysfunction Drugs Market Size, Share, and Trends 2024 to 2033

Erectile Dysfunction Drugs Market Size and Growth

The global erectile dysfunction drugs market size was USD 2.69 billion in 2023, estimated at USD 2.93 billion in 2024, and is expected to reach around USD 6.26 billion by 2033, expanding at a CAGR of 8.82% from 2024 to 2033. There is a growing demand for erectile dysfunction (ED) drugs owing to the adoption of a sedentary lifestyle, and associated stress can drive the erectile dysfunction drugs market growth.

Erectile Dysfunction Drugs Market Key Takeaways

• The North America erectile dysfunction drugs market size reached USD 1.43 billion in 2023 and is predicted to attain around USD 3.35 billion by 2033, at a CAGR of 8.88% from 2024 to 2033.
• North America dominated the market with the largest revenue share of 53% in 2023.
• Asia Pacific is expected to grow at the fastest CAGR of 10.21% during the forecast period.
• By product, the viagra segment has held a major revenue share of 57% in 2023.
• By product, the other segment is expected to witness fast growth in the market over the forecast period.

U.S. Erectile Dysfunction Drugs Market Size and Growth 2024 to 2033

The U.S. erectile dysfunction drugs market size was valued at USD 1 billion in 2023 and is expected to be worth around USD 2.36 billion by 2033 with a CAGR of 8.96% from 2024 to 2033.

North America dominated the erectile dysfunction drugs market in 2023. The availability of affordable generic products improves patient compliance by expanding the consumer base and boosting market revenue. In this region, the high prevalence of erectile dysfunction among a significant portion of the male population drives the demand for effective treatment options.

The United States is a major contributor to the North American erectile dysfunction drugs market. The market growth is driven by a large aging population, lifestyle-related diseases such as diabetes and hypertension, and increasing awareness of erectile dysfunction treatment options. Pharmaceutical companies like Pfizer and Eli Lilly have a strong presence, giving medications such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) through various distribution channels, including retail pharmacies and online platforms.

• In July 2023, Haleon stepped into the U.S. OTC erectile dysfunction market with a commercialization deal for Futura's drug-free MED3000 gel, recently approved by the FDA as a de novo medical device. Initially, it was $4m to commercialize Futura’s topical treatment, which was recently approved by the U.S. Food and Drug Administration as an OTC medical device.

Asia Pacific is expected to grow at the fastest rate in the erectile dysfunction drugs market during the forecast period. The growth of the Asia Pacific erectile dysfunction drugs market is driven by a rising middle class, increasing awareness of erectile dysfunction, and a growing number of patients willing to pay for treatment. The introduction of new products in the region has also contributed to this growth.

Market Overview

Erectile dysfunction is the inability to achieve or maintain an erection firm enough for sexual intercourse. This condition, sometimes referred to as impotence, though this term is now less common, can occasionally occur and is not unusual during times of stress. Persistent erectile dysfunction, however, may signal underlying health issues requiring medical attention or emotional and relationship problems that might benefit from professional intervention.

Erectile dysfunction can result from problems at any stage of the erection process. An erection is caused by increased blood flow to the penis, typically triggered by sexual thoughts or physical contact. When sexually aroused, the muscles in the penis relax, allowing blood to flow through the penile arteries and fill two chambers inside the penis. As these chambers fill with blood, the penis becomes rigid. An erection ends when the muscles contract, permitting the accumulated blood to flow out through the penile veins.

Erectile Dysfunction Drugs Market Growth Factors

• The rising geriatric population, along with patient awareness and education levels, is expected to fuel the erectile dysfunction drugs market growth.
• Various government reforms and initiatives can drive the erectile dysfunction drugs market further.
• The growing number of manufacturers of generic drugs will likely help in the erectile dysfunction drugs market expansion shortly.
• Increasing research and development investments can boost the growth of the erectile dysfunction drugs market.

Erectile Dysfunction Drugs Market Scope

Erectile Dysfunction Drugs Market Dynamics

Driver

Adoption of poor lifestyle choices

The prevalence of diabetes, obesity, and heart disease is increasing due to poor lifestyle choices, contributing to the rise of erectile dysfunction (ED) as individuals age. This drives the growth of the erectile dysfunction drugs market. Many young people in emerging countries experience stressful lifestyles, leading to higher consumption of fast food, alcohol, smoking, and ready-to-eat meals. These habits can deteriorate health and fitness, raising the likelihood of developing erectile dysfunction and needing treatment.

The demand for erectile dysfunction medications is growing and driving market expansion. Technological advancements, such as the development of new dosage forms, collaborations, and regulatory approvals, are further propelling the growth of the erectile dysfunction drugs market during the forecast period.

• In September 2023, Akums launched a drug for enlarged prostate & erectile dysfunction treatment. This innovative combined therapy, delivered in a fixed dose combination within a hard gelatin capsule, marks an important achievement.

Restraint

Side effects

The various side effects associated with erectile dysfunction drugs limit their adoption and negatively impact the erectile dysfunction drugs market growth. Common side effects of these medications include facial flushing, headaches, and back pain. More severe side effects can include vision loss, hearing loss, and prolonged erections lasting more than four hours. Additionally, erectile dysfunction drugs can interact with other medications, such as nitrates, which can lead to a significant drop in blood pressure. Therefore, all erectile dysfunction medications should be used under the guidance of healthcare professionals.

Opportunity

Rise in online pharmacies

The rise of online pharmacies has transformed the erectile dysfunction drugs market. Companies such as Hims & Hers, Roman, and Blue Chew use digital platforms to offer telemedicine consultations and direct-to-consumer delivery of erectile dysfunction drugs. The convenience of online pharmacies and the ease of obtaining prescriptions online have attracted consumers, particularly those uncomfortable discussing erectile dysfunction in person or seeking more private solutions. These platforms meet the demand for convenience, privacy, and discreet access to erectile dysfunction medications by eliminating the need for in-person visits to healthcare providers or traditional pharmacies.

• In January 2024, Pfizer Consumer Healthcare announced its largest pharmacy training program to date to support pharmacists and pharmacy assistants in advance of the launch of Viagra Connect (sildenafil 50mg) as a Pharmacy (P) medicine for the treatment of erectile dysfunction (ED) in men aged 18 and over.

Product insights

The viagra segment dominated the erectile dysfunction drugs market in 2023. Companies are pursuing strategic initiatives, including research collaborations, partnerships, and agreements, to expand their market presence. Viagra stands out among other phosphodiesterase 5 (PDE 5) inhibitors due to its long duration of action and fewer side effects, such as muscle pain and visual disturbances. Also, the increased effectiveness and performance of novel molecule types and drug delivery methods, such as creams and pellets, can further drive market growth.

• In May 2024, the Delhi High Court affirmed that the American pharmaceutical giant Pfizer exclusively owns the trademark 'Viagra,' a medication widely used to treat erectile dysfunction. In the legal battle, Pfizer Products Inc v Renovision Exports Private Limited and another, Justice Sanjeev Narula, ruled that Pfizer has the rightful registration of the 'Viagra' trademark, thus barring other entities from using the same or similar marks.

The other segment is expected to witness fast growth in the erectile dysfunction drugs market over the forecast period. The widespread availability and application of erectile dysfunction medicines, such as Helleva (vardenafil carbonate) and Mvix (sildenafil), cater to adult patients with erectile dysfunction. The growing approval of over-the-counter erectile dysfunction products has made access to these treatments easier. This trend enhances the accessibility of erectile dysfunction medications by allowing more patients to obtain necessary treatments conveniently.

Erectile Dysfunction Drugs Market Companies

• Pfizer Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Petros Pharmaceuticals, Inc.
• VIVUS, Inc.
• Auxilium Pharmaceuticals, Inc.
• Adamed
• Cipla Inc.

Recent Developments

• In January 2023, Petros Pharmaceuticals, Inc. initiated two self-selection studies for its erectile dysfunction drug STENDRA (avanafil).
• In February 2023, Astellas Pharma announced the launch of Vyleesi (bremelanotide) in the United States. Vyleesi is a new injectable medication for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
• In March 2022, the U.S. FDA permitted Lupin to commercialize a generic version of Revatio from Viatris Specialty LLC. Lupin's ANDA for sildenafil (10 mg/mL oral suspension) gained this approval
• In May 2022, Aspargo Laboratories, Inc. purchased the prescription brand Bandol from the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. Bandol is used to treat patients with ED problems.
• In February 2022, Tadalafil MAXON was first approved for marketing authorization by a Polish business, Adamed, under the OTC (over-the-counter) category.

Segments Covered in the Report

By Product

• Viagra
• Cialis
• Zydena
• Levitra
• Stendra
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa